- CLN-PXT3003-06_PREMIER: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)
- MetaDLM_CMT2A: Metabolomic exploration of lipid metabolism dysregulation in Mitofusin 2-related Charcot-Marie-Tooth disease type 2A (CMT2A)
Acronym |
CLN-PXT3003-06_PREMIER |
MetaDLM_CMT2A |
| Pathology | CMT1A | CMT2A |
| Intervention | PXT3003 | – |
| Principal investigator | Giorgia Querin | Tanya Stojkovic |
| Sponsor | Pharnext | CHU Angers |
| Study status | Ongoing | Ongoing |
| Recruitment status | Completed | Ongoing |
| Population | Adult | Adult |
| + infos on clinical trials.gov | + infos sur clinicaltrials.gov |
